TABLE 4.

The anti-CD25 PC61 mAb enables the adoptive transfer of EAE in Csf2^−/− mice

Strain	Donors	Recipients	Incidence	Mean cumulative score	Median cumulative score	Mean maximal score	Median maximal score	Mean maximal weight loss	Mean average weight loss
(a) Csf2−/−	PC61	PC61	4 of 4	109.7 ± 7.4	108.5	4.0 ± 0.0	4.0	20.4%	13.7%
(b) Csf2−/−	PC61	Saline	4 of 4	53.8 ± 19.1	60.3	3.0 ± 0.7	3.5	17.9%	12.4%
(c) Csf2−/−	Saline	PC61	0 of 4	0.0 ± 0.0	0.0	0.0 ± 0.0	0.0	0.0%	−3.0%
(d) Csf2−/−	Saline	Saline	0 of 4	0.0 ± 0.0	0.0	0.0 ± 0.0	0.0	0.0%	−0.8%
(e) C57BL/6	PC61	PC61	4 of 4	119.8 ± 1.8	120.3	4.0 ± 0.0	4.0	26.9%	21.2%
(f) C57BL/6	PC61	Saline	4 of 4	67.6 ± 4.6	71.0	4.0 ± 0.0	4.0	28.1%	17.7%
(g) C57BL/6	Saline	PC61	4 of 4	123.5 ± 2.1	123.0	4.0 ± 0.0	4.0	22.5%	18.4%
(h) C57BL/6	Saline	Saline	4 of 4	91.9 ± 12.8	81.0	4.0 ± 0.0	4.0	27.3%	18.0%
(c) and (d) vs. (a), (e), (g), and (h)			P = 0.0286	P ≤ 0.002		P ≤ 0.001		P ≤ 0.001	P ≤ 0.017

These data are portrayed in Fig. 4. Donor Csf2^−/− and control C57BL/6 mice were or were not treated with 250 µg PC61 on d −5 and −3 and were immunized with 200 µg MOG35–55 in CFA on d 0. On d 11, draining lymph nodes and spleen were pooled within each of the 4 donor groups. These cells were cultured for 3 d with 1 µM MOG35–55 and 10 ng/ml IL-23. Activated donor T cells were then adoptively transferred into recipients (10⁷ cells/recipient). Csf2^−/− T cells were injected into Csf2^−/− recipients, and C57BL/6 T cells were injected into C57BL/6 recipients. On d 7, each recipient group was or was not injected with 250 µg PC61. Shown are the means and the sem for cumulative and maximal EAE scores. Differences in EAE and weight-loss values were assessed by nonparametric and parametric ANOVA, respectively. Differences in disease incidence were assessed pairwise by a Fisher’s exact test.